Evidence map›Paper›PMID 38225969›Full record

ArticleJournal of Alzheimer's disease reports2023

Modulation of Cytosolic Phospholipase A2 as a Potential Therapeutic Strategy for Alzheimer's Disease.

Séverine André, Sébastien Verteneuil, Laurence Ris, Zehra-Cagla Kahvecioglu, Denis Nonclercq, Julien De Winter, Luce Vander Elst, Sophie Laurent, Robert N Muller, Carmen Burtea

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Phospholipase A2 downregulates inhibitory transmission in the amygdala and impairs fear extinction.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  2. The Phospholipase AJournal of lipid and atherosclerosis · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Séverine AndréGeneral, Organic and Biomedical Chemistry Unit, NMR and Molecular Imaging Laboratory, University of Mons, Mons, Belgium.
Sébastien VerteneuilGeneral, Organic and Biomedical Chemistry Unit, NMR and Molecular Imaging Laboratory, University of Mons, Mons, Belgium.
Laurence RisDepartment of Neurosciences, University of Mons, Research Institute for Health Science and Technologies, Mons, Belgium.
Zehra-Cagla KahveciogluGeneral, Organic and Biomedical Chemistry Unit, NMR and Molecular Imaging Laboratory, University of Mons, Mons, Belgium.
Denis NonclercqDepartment of Histology, University of Mons, Mons, Belgium.
Julien De WinterOrganic Synthesis and Mass Spectrometry Laboratory (SMOs), University of Mons-UMONS, Mons, Belgium.
Luce Vander ElstGeneral, Organic and Biomedical Chemistry Unit, NMR and Molecular Imaging Laboratory, University of Mons, Mons, Belgium.
Sophie LaurentGeneral, Organic and Biomedical Chemistry Unit, NMR and Molecular Imaging Laboratory, University of Mons, Mons, Belgium.
Robert N MullerGeneral, Organic and Biomedical Chemistry Unit, NMR and Molecular Imaging Laboratory, University of Mons, Mons, Belgium.
Carmen BurteaGeneral, Organic and Biomedical Chemistry Unit, NMR and Molecular Imaging Laboratory, University of Mons, Mons, Belgium.
University of Mons · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alzheimer's disease (AD) is a neurodegenerative disorder lacking any curative treatment up to now. Indeed, actual medication given to the patients alleviates only symptoms. The cytosolic phospholipase A2 (cPLA Objective: A cPLA Methods: We targeted the cPLA Results: Showing a high affinity for the C2 domain of this enzyme, the peptide PLP25 exhibited an inhibitory effect on cPLA Conclusions: cPLA

Indexed as

Alzheimer’s diseaseamyloid plaquesamyloid-β protein precursorcytosolic phospholipase A2peptidesphage displaytau protein

Identifiers

PMID38225969
PMCPMC10789292
OpenAlexW4390398559

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.